MetaCap

Maravai LifeSciences Holdings Inc. Class A (MRVI)

NASDAQ: MRVIHealth CareBiotechnology: Pharmaceutical PreparationsUSD

6.98-0.21 (-2.92%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MRVI stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.44
52-week range
2.80 – 9.42
Day range
6.91 – 7.17
Volume / Avg
1.79M / 2.72M
Beta
—

52-week range

$2.80$9.42

MRVI stock today

Shares of Maravai LifeSciences (MRVI) finished lower on Nov 20 at $6.98, a drop of 2.92% or $0.21 per share, versus the S&P 500's 3.70% decline. At this level, MRVI sits in the middle of its 52-week range of $2.80 to $9.42: 25.9% below the high, set on Aug 26, 2026 and 149.3% above the low. MRVI is up 114.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 86.1%.

Maravai LifeSciences has posted a net loss over the last twelve months (EPS of -$0.44), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Maravai LifeSciences

Company profile

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Bernd Brust
Headquarters
San Diego, CA
Employees
410
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Maravai LifeSciences generated $185.7 million in revenue, down 28.3% from fiscal 2024, its first annual decline since 2024. Maravai LifeSciences reported a net loss of $130.8 million, compared with a loss of $144.8 million a year earlier. Gross margin was 18.3% (down from 41.8%) and operating margin -115.9%.

Maravai LifeSciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$185.74M$259.19M$288.94M$883.00M$799.24M
Growth-28.34%-10.30%-67.28%+10.48%+181.33%
Net income$-130.77M$-144.85M$-119.03M$220.21M$182.04M
EPS (diluted)$-0.90$-1.05$-0.90$1.67$1.56

Analyst forecast

Forecast

Consensus (9 analysts)

buy

Avg. price target

$9.64+38.11%

  • Strong buy 0
  • Buy 6
  • Hold 3
  • Sell 0
  • Strong sell 0

Target range

Low $8.00High $12.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.14 vs $-0.07
Surprise
-100.00%

MRVI news

All MRVI news

Maravai LifeSciences peers

Health Care sector
MRVI peer companies
CompanyPrice% ChgMarket capCompare
ZYMEZymeworks Inc.26.14-2.68%$1.81Bvs MRVI
SEPNSepterna Inc.38.61-1.51%$1.84Bvs MRVI
VERAVera Therapeutics Inc. Class A25.45-4.86%$1.84Bvs MRVI
IMNMImmunome Inc.15.69-5.54%$1.85Bvs MRVI
BHVNBiohaven Ltd.12.39-9.23%$1.87Bvs MRVI
ETONEton Pharmaceuticals Inc.60.85-0.83%$1.76Bvs MRVI
STOKStoke Therapeutics Inc.26.81-0.45%$1.75Bvs MRVI
TRAXFirst Tracks Biotherapeutics Inc.41.64-6.34%$1.75Bvs MRVI

Indexes, lists and sector

Maravai LifeSciences stock FAQ

What is Maravai LifeSciences's stock price today?

MRVI last traded at $6.98 as of Nov 20, 4:00 PM EST, down 2.92% on the day. Prices are delayed at least 15 minutes.

Who is Maravai LifeSciences's CEO?

Mr. Bernd Brust is the chief executive officer of Maravai LifeSciences Holdings Inc. Class A, which has about 410 employees.

What is the MRVI 52-week high?

The 52-week high for MRVI is $9.42 and the 52-week low is $2.80. The stock is currently 25.9% below its high.

Compare MRVI